Reports Q3 revenue $22.5B, consensus $22.16B. “Johnson & Johnson’s strong results in the third quarter reflect the unique breadth of our business and commitment to delivering the next wave of healthcare innovation,” said Joaquin Duato, Chairman and Chief Executive Officer. “During the quarter, we advanced our pipeline with regulatory approvals for TREMFYA and RYBREVANT, submitted an IDE for our general surgery robotic system, OTTAVA, and launched VELYS Spine and Shockwave E8 IVL Catheter, further strengthening our confidence in our near-and long-term growth targets.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Notable companies reporting before tomorrow’s open
- Eli Lilly’s (NYSE:LLY) Crohn’s Disease Drug Outperforms JNJ’s Version
- Options Volatility and Implied Earnings Moves This Week, October 15 – October 18, 2024
- Johnson & Johnson (JNJ) Q3 Pre-Earnings: Here’s What to Expect
- Johnson & Johnson (JNJ) Q3 Earnings Cheat Sheet